Recent developments in the therapy of phaeochromocytoma

Bibliography

• COUPLAND RE: On the morphology andadrenaline-noradrenaline content of chromaffin tissue. I Endocrine]. (1953) 9:194–203.
   Web of Science ®Google Scholar
• BRAVO EL, TAGLE R: Pheochromocytoma: state-of-the-art and future prospects. Endocc Rev (2003) 24:539–553.
   PubMed Web of Science ®Google Scholar
• EISENHOFER G, BORNSTEIN SR, BROUWERS FM et al.: Malignant pheochromocytoma: current status and initiatives for future progress. Endocc Relat Cancer (2004) 11:423–436.
   PubMed Web of Science ®Google Scholar
• ROSS EJ, PRICHARD BN, KAUFMAN L, ROBERTSON AT, HARRIES BJ: Preoperative and operative management of patients with phaeochromocytoma. Br. Med.j. (1967) 28:191–198.
   Google Scholar
• ••Classic paper on the safe management ofphaeochromocytoma.
   Google Scholar
• PLOUIN PF, DUCLOS JM, SOPPELSA F, BOUBLIL G, CHATELLIER G: Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J. Clin. Endocrine]. Metab. (2001) 86:1480-1486. Expert Op/n. Investig. Drugs (2004) 13(12)1581
   Google Scholar
• •Data indicate the independent effect of control of pre-operative blood pressure on surgical morbidity and mortality.
   Google Scholar
• BEATTY OL, RUSSELL CE KENNEDY L, HADDEN DR, KENNEDY TL, ATKINSON AB: Phaeochromocytoma in Northern Ireland: a 21 year review. Eur.J Surg. (1996) 162:695–702.
   PubMedGoogle Scholar
• BOUTROS AR, BRAVO EL, ZANETTIN G, STRAFFON RA: Perioperative management of 63 patients with pheochromocytoma. Cleve. Clin. Med. (1990) 57:613–617.
   PubMed Web of Science ®Google Scholar
• TAUZIN-FIN P, SESAY M, GOSSE P, BALLANGER P: Effects of perioperative CU block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br. Anaesth. (2004) 92:512–517.
   PubMed Web of Science ®Google Scholar
• PROYE C, THEVENIN D, CECAT P et al: Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery (1989) 106:1149–1154.
   PubMed Web of Science ®Google Scholar
• JORIS JL, HAMOIR EE, HARTSTEIN GM et al.: Hemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Anesth. Analg. (1999) 88:16–21.
   PubMed Web of Science ®Google Scholar
• COLSON P, RYCKWAERT F, RIBSTEIN J, MANN C, DAREAU S: Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery. Acta Anaesthesia Scand. (1998) 42:1114–1119.
   PubMed Web of Science ®Google Scholar
• BRIGGS RS, BIRTWELL AJ, POHL JE:Hypertensive response to labetalol in phaeochromocytoma. Lancet (1978) 1:1045–1046.
   PubMed Web of Science ®Google Scholar
• FEEK CM, EARNSHAW PM: Hypertensive response to labetalol in phaeochromocytoma. Br. Med. J. (1980) 281:387.
   PubMed Web of Science ®Google Scholar
• NAVARATNARAJAH M, WHITE DC: Labetalol and phaeochromocytoma. Br. Anaes. (1984) 56:1179.
   PubMed Web of Science ®Google Scholar
• RUSSELL WJ, KAINES AH, HOOPER MJ, FREWIN DB: Labetalol in the preoperative management of phaeochromocytoma. Anaesth. Intensive Care (1982) 10:160–163.
   PubMed Web of Science ®Google Scholar
• RUSSELL WJ, METCALFE IR, TONKIN AL, FRE WIN DB: The preoperative management of phaeochromocytoma. Anaesth. Intensive Care (1998) 26:196–200.
   PubMed Web of Science ®Google Scholar
• SHEAVES R, CHEW SL, GROSSMAN A: The dangers of unopposed I3-adrenergic blockade in phaeochromocytoma. Postgrad. Med. J. (1995) 71:58–59.
   PubMed Web of Science ®Google Scholar
• SAND J, SALMI J, SAARISTO J, AUVINEN 0: Preoperative treatment and survival of patients with pheochromocytomas. Ann. Chir Cynaecol (1997) 86:230–232.
   PubMedGoogle Scholar
• STEINSAPIR J, CARR AA, PRISANT LM, BRANSOME ED Jr: Metyrosine and pheochromocytoma. Arch. Intern. Med. (1997) 157:901–906.
   PubMed Web of Science ®Google Scholar
• BRUNT LM: The positive impact of laparoscopic adrenalectomy on complications of adrenal surgery. Sag. Enclose. (2002) 16:252–257.
   Google Scholar
• TRAINER PJ, BESSER GM: The Bart's endocrine protocols. PJ Trainer, GM Besser (Eds), Churchill Livingstone, London, UK (1995).
   Google Scholar
• GAGNER M, LACROIX A, BOLTE E: Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N. Engl. Med. (1992) 327:1033.
   PubMed Web of Science ®Google Scholar
• •First description of laparoscopic adrenalectomy.
   Google Scholar
• JAROSZEWSKI DE, TESSIER DJ, SCHLINKERT RT et al.: Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clin. Proc. (2003) 78:1501–1504.
   PubMed Web of Science ®Google Scholar
• BRAUCKHOFF M, GIMM 0, THANH PN et al.: Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery (2003) 134:1020–1027.
   Google Scholar
• LAL G, DUH QY: Laparoscopic adrenalectomy-indications and technique. Surg. Oncol (2003) 12:105–123.
   PubMed Web of Science ®Google Scholar
• BENTREM DJ, PAPPAS SG, AHUJA Y, MURAYAMA KM, ANGELOS P: Contemporary surgical management of pheochromocytoma. Am. j Surg. (2002) 184:621–624.
   PubMed Web of Science ®Google Scholar
• CHEAH WK, CLARK OH, HORN JK, SIPERSTEIN AE, DUH QY: Laparoscopic adrenalectomy for pheochromocytoma. World J. Surg. (2002) 26:1048–1051.
   PubMed Web of Science ®Google Scholar
• LI ML, FITZGERALD PA, PRICE DC, NORTON JA: Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy. Surgery (2001) 130:1072–1077.
   PubMed Web of Science ®Google Scholar
• YIP L, LEE JE, SHAPIRO SE et al: Surgical management of hereditary pheochromocytoma. I Am. Coll. Surg. (2004) 198:525–534.
   PubMed Web of Science ®Google Scholar
• ••Includes data on recurrance rates aftercortical-sparing adrenalectomy.
   Google Scholar
• NEUMANN HP, REINCKE M, BENDER BU, ELSNER R, JANETSCHEK G: Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. Clin. Endocrina Metab (1999) 84:2608–2610.
   PubMed Web of Science ®Google Scholar
• ••First description of cortical-sparingadrenalectomy in familial disease.
   Google Scholar
• SAFFORD SD, COLEMAN RE, GOCKERMAN JP et al: Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 134:956–962.
   PubMed Web of Science ®Google Scholar
• EDSTROM EE, HJELM SKOG AL, HOOG A, HAMBERGER B: The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur. .1 Surg. Omni (2003) 29:278–283.
   Web of Science ®Google Scholar
• MUKHERJEE JJ, KALTSAS GA, ISLAM N et al.: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG1. Clin. Endocrina (2001) 55:47–60.
   PubMed Web of Science ®Google Scholar
• LOH KC, FITZGERALD PA, MATTHAY KK, YEO PP, PRICE DC: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (13 1I-MIBG): a comprehensive review of 116 reported patients. Endocrina Invest. (1997) 20:648–658.
   PubMed Web of Science ®Google Scholar
• •Major review of treatment for malignant disease with [131I]-MIBG.
   Google Scholar
• ROSE B, MATTHAY KK, PRICED et al: High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer (2003) 98:239–248.
   PubMed Web of Science ®Google Scholar
• ••First experience of high dose [1-31I]-MIBGtherapy.
   Google Scholar
• AVERBUCH SD, STEAKLEY CS, YOUNG RC et al.: Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, 1582 Expert Op/n. Investig. Drugs (2004)13(12) vincristine, and dacarbazine. Ann. Intern. Med. (1988) 109:267–273.
   Google Scholar
• SISSON JC, SHAPIRO B, SHULKIN BL, URBA S, ZEMPEL S, SPAULDING S: Treatment of malignant pheochromocytomas with 131-1 metaiodobenzylguanidine and chemotherapy. Arm Clin. Oncol. (1999) 22:364–370.
   PubMed Web of Science ®Google Scholar
• ••Combined treatments may bringadditional responses in some patients.
   Google Scholar
• YOSHIDA S, HATORI M, NOSHIRO T, KIMURA N, KOKUBUN S: Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch. Orthop. Trauma Surg. (2001) 121:598–600.
   PubMed Web of Science ®Google Scholar
• KERGER BD, JAMES RC, ROBERTS SM: An assay for phentolamine using high performance liquid chromatography with electrochemical detection. Anal. Biochem. (1988) 170:145–151.
   PubMed Web of Science ®Google Scholar
• MIHM FG, SANDHU JS, BROWN MD, ROSENTHAL MH: Short-acting P-adrenergic blockade as initial drug therapy in pheochromocytoma. Crit. Care Med. (1990) 18:673–674.
   PubMed Web of Science ®Google Scholar